Carregant...

Treatment With Bevacizumab Plus Carboplatin for Recurrent Malignant Glioma

OBJECTIVE: To estimate overall survival (OS), progression-free survival (PFS), imaging responses, and toxicities of bevacizumab plus carboplatin for the treatment of recurrent malignant glioma. The secondary objective was to estimate the agreement between post-contrast T1-weighted and T2-weighted ma...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurosurgery
Autors principals: Thompson, Eric M., Dosa, Edit, Kraemer, Dale F., Neuwelt, Edward A.
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4905718/
https://ncbi.nlm.nih.gov/pubmed/20559095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1227/01.NEU.0000370918.51053.BC
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!